Skip to main content
Top
Published in: Clinical and Experimental Nephrology 4/2016

Open Access 01-08-2016 | Guideline

Evidence-based clinical practice guidelines for IgA nephropathy 2014

Authors: Yukio Yuzawa, Ryohei Yamamoto, Kazuo Takahashi, Ritsuko Katafuchi, Makoto Tomita, Yoshihide Fujigaki, Hiroshi Kitamura, Masashi Goto, Takashi Yasuda, Mitsuhiro Sato, Maki Urushihara, Shuji Kondo, Shoji Kagami, Yoshinari Yasuda, Hiroyuki Komatsu, Miki Takahara, Yasuaki Harabuchi, Kenjiro Kimura, Seiichi Matsuo

Published in: Clinical and Experimental Nephrology | Issue 4/2016

Login to get access

Excerpt

Immunoglobulin A (IgA) nephropathy (IgAN) is the most common primary glomerulonephritis, and patients typically require dialysis when the disease progresses to end-stage renal failure. As the incidence of IgAN is high in Asian populations, including Japanese, establishing a treatment strategy in Japan is strongly warranted. In 1995, the joint committee of the Special Study Group of the Progressive Renal Dysfunction Research Group of the Ministry of Health Labour and Welfare (MHLW) and the Japanese Society of Nephrology (JSN) developed the Clinical Practice Guides for IgAN for the first time. Its second version was published with a partial amendment in 2002. The third version, published in 2011, analyzed data from a multicenter study conducted mainly by the Research Group for IgAN in the Progressive Renal Dysfunction Research Group of MHLW to propose a novel prognostic classification (risk stratification for dialysis), adding clinical severity to histological severity. These clinical practice guides present clear prognostic criteria and treatment guidelines according to the criteria. Therefore, these guides have been widely used in clinical practice or pathological diagnosis, and they have contributed to the diagnosis and treatment of IgAN in Japan. …
Metadata
Title
Evidence-based clinical practice guidelines for IgA nephropathy 2014
Authors
Yukio Yuzawa
Ryohei Yamamoto
Kazuo Takahashi
Ritsuko Katafuchi
Makoto Tomita
Yoshihide Fujigaki
Hiroshi Kitamura
Masashi Goto
Takashi Yasuda
Mitsuhiro Sato
Maki Urushihara
Shuji Kondo
Shoji Kagami
Yoshinari Yasuda
Hiroyuki Komatsu
Miki Takahara
Yasuaki Harabuchi
Kenjiro Kimura
Seiichi Matsuo
Publication date
01-08-2016
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 4/2016
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-015-1223-y

Other articles of this Issue 4/2016

Clinical and Experimental Nephrology 4/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.